Idelalisib resulted in a CD4:CD8 ratio in chronic lymphocytic leukemia (CLL) patient-derived CAR-T cells that was closer to the ratio in healthy donors [68]. This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.